MD Conference Express EASD 2012 - (Page 11)

According to Dr. Inzucchi, glycemic targets and blood glucose-lowering therapies must be individualized. Diet, exercise, and education are the foundation of any T2DM therapy program. Unless contraindicated, metformin is the optimal first-line drug; however, more data are limited. Nonetheless, combination therapy with 1 to 2 other oral/injectable agents that minimize side effects is reasonable. Ultimately, many patients will require insulin therapy alone or in combination with other agents to maintain blood glucose (Figure 2). Figure 2. Antihyperglycemic Therapy. Evidence-Based Highlights with Peer-Reviewed integrity The world’s most influential key opinion leaders trust MD Conference Express® to deliver authoritative, balanced, and insightful highlights from the medical conferences that will change practice Our 5-Step Peer-Review Process: MD Conference Express® is issued to the medical community only after passing rigorous peer-review 5. Editors finalize publication 4. Independent expert peer-review ensures accuracy and fair balance 3. Presenting faculty confirm data and/or provide post-conference updates 2. Data-driven content referenced against primary sources Reproduced from Inzucchi SE et al. Management of Hyperglycemiain Type 2 Diabetes: A Patient-Centered Approach. Diabetes Care Jun 2012;35(10):1364-1379, with permission from the American Diabetes Association. Earlier guidelines focused drug treatment choices mainly on HbA1C levels after lifestyle modification [Robard H et al. Endocr Pract 2009]. For example, Nathan et al. [Diabetes Care 2008] recommended that clinicians check HbA1C levels every 3 months until <7.0%, then at least every 6 months thereafter, with new drug interventions whenever HbA1C levels reach ≥7.0%. The new ADA/EASD guidelines shift the focus on medication choices from HbA1C levels alone and add patient-centered considerations. Dr. Inzucchi emphasized the need to make all treatment decisions in conjunction with patients (with a focus on their preferences, needs, and values) and stressed that comprehensive cardiovascular risk reduction should be a major focus of therapy. 1. Scientific committee guides topic selection MD Conference Express fills the gap between live presentation and publication in the academic literature by applying the rigorous standard of peer-review to the creation of our medical conference highlights reports. For more information please visit: www.mdconferencexpress.com Like us on facebook www.facebook.com/mdconferencexpress A Product of Peer-Reviewed Highlights of the 48th Annual Meeting of the European Association for the Study of Diabetes 11  http://www.mdconferencexpress.com http://www.facebook.com/mdconferencexpress http://www.mdconferencexpress.com

Table of Contents for the Digital Edition of MD Conference Express EASD 2012

MD Conference Express EASD 2012
Contents
Understanding Incretin Hormone Action and the Treatment of Diabetes
New ADA/EASD Guidelines Focus on Patient-Centered Care
ORIGIN Trial: Insulin Glargine and n-3 Fatty Acids Fail to Reduce CV Events in Diabetic Patients
Exenatide Once Weekly Sustained Improvement in Glycemic Control with Weight Loss Through 4 Years
DiaPep277® Shows Promise as a Therapeutic Strategy for T1DM
Linagliptin Proves Safe and Effective as Add-on Therapy to Basal Insulin
12-Week Treatment with LY2409021 Significantly Lowers HbA1C and Is Well Tolerated in Patients with T2DM
Insulin Degludec Is Superior to Sitagliptin in Improving Glycemic Control in Uncontrolled Patients with Type 2 Diabetes on Oral Agents
Dapagliflozin Does Not Impact Renal Function in Patients with T2DM
Population-Based Screening for T2DM:The ADDITION-Cambridge Trial
The Challenges of Pharmaceutical Management of Painful Diabetic Peripheral Neuropathy
Enterovirus Infection
Novel Oral Agents
GLP-1
Genetics
Renal Denervation
Hypertension and Renal Function Are Risk Factors for CAD in T1DM

MD Conference Express EASD 2012

https://www.nxtbook.com/nxtbooks/md_conference_express/easd2012
https://www.nxtbookmedia.com